Multiple Myeloma | Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics: Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00) Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46) Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40) Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26) Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55) Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39) CME information and select publications